Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.
OBJECTIVE
Previous preclinical studies suggested that concurrent capecitabine and radiation could be an effective new treatment modality for glioblastoma (GBM). In the current study, we investigate toxicity and response to this regimen and explore associations between gene expression and patient outcome.


METHODS
Eighteen newly diagnosed GBM patients received concurrent capecitabine at 625 mg/m2 BID (25% escalation) and irradiation (60 Gy total) for 6 weeks followed by 4 weeks of capecitabine only. Maintenance capecitabine was administered for 14 days every 3 weeks until progression or unacceptable toxicity. Expression analysis of 94 genes involved in capecitabine metabolism and radiation response was done on tissues obtained before therapy. The relationship of gene expression with time-to-progression (TTP) and overall survival (OS) was investigated using univariate Cox proportional hazards regression, semi-supervised principle component analysis, and class prediction modeling.


RESULTS
The maximum tolerated dose of capecitabine was 625 mg/m2 BID. Median patient TTP and OS were 247 and 367 days, respectively. Cox regression identified 24 genes significantly (P<0.025) associated with patient outcome. Semi-supervised principle component analysis identified two patient populations significantly different in both TTP (P=0.005) and OS (P=0.015). Class prediction modeling determined that eight genes (RAD54B, MTOR, DCTD, APEX2, TK1, RRM2, SLC29A1, and ERCC6) could collectively classify patients into outcome subgroups with 100% accuracy and precision.


CONCLUSIONS
Capecitabine and concurrent radiation for newly diagnosed GBM seems to be well tolerated and comparable to temozolomide and radiation. A gene expression profile predictive of patient outcome that may be useful in patient stratification for therapy was also elucidated.
Grunda
Jessica M
JM
Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, Department of Radiation Oncology, Division of Neuropathology, Department of Pathology, Division of Preventive Medicine, Department of Medicine, and Division of Neuro-oncology, Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama.
Fiveash
John
J
Palmer
Cheryl A
CA
Cantor
Alan
A
Fathallah-Shaykh
Hassan M
HM
Nabors
L Burt
LB
Johnson
Martin R
MR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000235:genetics* / Q000628:therapy*; D000069287:Capecitabine; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D020869:Gene Expression Profiling; D005909:Glioblastoma / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics / Q000379:methods; D016016:Proportional Hazards Models; D011878:Radiotherapy; D055815:Young Adult
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
Invest New Drugs. 2000 Nov;18(4):343-54
11081570
J Mol Diagn. 2006 Feb;8(1):76-83
16436637
Am J Clin Oncol. 2001 Aug;24(4):421-4
11474279
Ann Oncol. 1998 Nov;9(11):1251-3
9862058
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
Oncologist. 2006 Oct;11(9):1003-9
17030642
Cancer. 2003 Oct 15;98(8):1745-8
14534892
Clin Cancer Res. 2003 Aug 1;9(8):2940-9
12912940
PLoS Biol. 2004 Apr;2(4):E108
15094809
Clin Cancer Res. 1999 Oct;5(10):2948-53
10537364
N Engl J Med. 2009 Jan 29;360(5):470-80
19129520
Neurosurgery. 1984 Jun;14(6):679-81
6087193
Ann Oncol. 2001 Feb;12(2):259-66
11300335
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
J Natl Cancer Inst. 1972 Dec;49(6):1577-84
4265113
Nature. 2000 Feb 3;403(6769):503-11
10676951
Cancer J. 2007 Jul-Aug;13(4):247-56
17762760
Cancer Sci. 2004 Nov;95(11):851-7
15546501
Neurosurgery. 1982 Aug;11(2):213-8
6289163
Cancer Chemother Pharmacol. 2000;45(4):291-7
10755317
Pharmacol Ther. 2003 Apr;98(1):71-108
12667889
Neurol Med Chir (Tokyo). 1984 Feb;24(2):65-72
6205290
J Neurooncol. 1995;23(3):249-52
7673988
JAMA. 2009 Jul 15;302(3):261-75
19602686
Mol Cancer Ther. 2002 Oct;1(12):1139-45
12481438
Pharm Res. 2001 Aug;18(8):1190-202
11587492
Cancer Res. 1998 Feb 15;58(4):685-90
9485021
Biochem Pharmacol. 2007 Dec 3;74(11):1555-67
17572389
J Clin Oncol. 2005 Dec 1;23(34):8679-87
16314628
J Clin Oncol. 1999 Sep;17(9):2762-71
10561351
Anal Biochem. 2002 Apr 15;303(2):209-14
11950223
Nature. 2008 Oct 23;455(7216):1061-8
18772890
J Neurooncol. 2006 Dec;80(3):261-74
16773218
Neurol Med Chir (Tokyo). 1985 Aug;25(8):613-9
2415854
J Neurooncol. 1996 Dec;30(3):243-6
8943099
Cancer Res. 1973 Jul;33(7):1735-46
4198466
Neurosurgery. 2005 Feb;56(2):242-8; discussion 242-8
15670372